Circulating thrombospondin 1 level as a surrogate marker in patients receiving cyclophosphamide-based metronomic chemotherapy

Investigational New Drugs

Volumn 30, Issue 1, 2012, Pages 403-404

  Lansiaux, Amélie ^a,b   Salingue, Sophie ^a   Dewitte, Amélie ^a   Clisant, Stéphanie ^a   Penel, Nicolas ^a,c  

^a CENTRE OSCAR LAMBRET   (France)

^b Institut de Recherche sur le Cancer de Lille   (France)

^c UNIV LILLE   (France)

Author keywords

Cyclophosphamide; Metronomic chemotherapy; Thrombospondin

Indexed keywords

BIOLOGICAL MARKER; CYCLOPHOSPHAMIDE; MEGESTROL ACETATE; THROMBOSPONDIN 1;

ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; COLON CANCER; CONTROLLED STUDY; DISEASE MARKER; DOWN REGULATION; DRUG EFFECT; DRUG RESPONSE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MELANOMA; METRONOMIC DRUG ADMINISTRATION; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL; RECTUM CANCER; SARCOMA;

ADMINISTRATION, METRONOMIC; ANTINEOPLASTIC AGENTS, ALKYLATING; CYCLOPHOSPHAMIDE; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FRANCE; HUMANS; NEOPLASMS; THROMBOSPONDIN 1; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84856557454     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-010-9443-1     Document Type: Article

References (5)

1. Kerbel RS, Klement G, Prichard KI, Kamen B (2002) Continuous low dose antiangiogenic/metronomic chemotherapy: From the research laboratory into the oncology clinic. Ann Oncol 13:12-15 (Pubitemid 34436715)
2. Buckstein R, Kerbel RS, Shaked Y, Noyar R, Foden C, Turner R et al (2006) High-dose celecoxib and metronomic "low dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma. Clin Cancer Res 12:5190-5198 (Pubitemid 44453348)
3. Bocci G, Francia G, Man S, Lanler S, Kerbel RS (2003) Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc Natl Acad Sci USA 100:1297-1222
4. Damber JE, Vallbo C, Albertsson P, Lennernäs B, Norrby K (2006) The antitumor effect of low-dose continuous chemotherapy may partly be mediated by thrombospondin. Cancer Chemother Pharmacol 58:354-360 (Pubitemid 43800739)
5. Penel N, Clisant S, Dansin E, Desauw C, Dégardin M, Mortier L et al (2010) Megestrol acetate versus metronomic cyclophosphamide in patients having exhausted all effective therapies under standard care. Br J Cancer 102:1207-1212